Welcome to our dedicated page for Immunome news (Ticker: $IMNM), a resource for investors and traders seeking the latest updates and insights on Immunome stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Immunome's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Immunome's position in the market.
Immunome (Nasdaq: IMNM) has announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Rosett, previously Executive Vice President of Operations and Interim CFO since January 2024, has played a key role in Immunome's recent strategic moves including the merger with Morphimmune and financial transactions worth over $350 million. CEO Clay Siegall emphasized Rosett's strategic insight and financial expertise as vital for advancing the company's pipeline, including the Phase 3 RINGSIDE trial of AL102 and preparing IM-1021 and IM-3050 for IND submission. Rosett's background includes senior roles at Morphimmune and experience at Research Bridge Partners, Google, and Boston Consulting Group.
Immunome (Nasdaq: IMNM), a biotech company focused on targeted cancer therapies, reported its Q1 2024 financial results and provided a business update. The company has integrated AL102 and IM-1021 and is progressing towards regulatory submissions. Topline data for the Phase 3 RINGSIDE trial of AL102 is expected in H2 2025. IND submissions for IM-1021 and IM-3050 are anticipated in Q1 2025. Financially, Immunome has $309.7 million in cash and equivalents, with a runway extending into 2026. Q1 2024 expenses included $15.4 million in R&D, $112 million in in-process R&D from recent acquisitions, and $6 million in administrative costs. The company posted a net loss of $129.5 million, or $2.51 per share.
Immunome, Inc. (IMNM) will be presenting at the 2024 Bank of America Healthcare Conference. The President and CEO, Clay Siegall, will present on May 15, 2024. Interested parties can access the live webcast on the company's website.
Immunome, Inc. (Nasdaq: IMNM) has appointed Kinney Horn as Chief Business Officer, bringing extensive experience in life sciences corporate and business development to the company. With the recent acquisition of AL102, Immunome is now a clinical stage company, aiming to enhance its development capabilities and expand its portfolio of targeted cancer therapies. Mr. Horn's successful track record in strategic partnerships will play a important role in Immunome's growth.